for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Novartis AG

NVSEF.PK

Latest Trade

91.66USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

68.65

 - 

98.00

As of on the Virt-X ∙ Minimum 15 minute delay

Pricing

Previous Close
91.66
Open
--
Volume
--
3M AVG Volume
116.04
Today's High
--
Today's Low
--
52 Week High
98.00
52 Week Low
68.65
Shares Out (MIL)
2,288.98
Market Cap (MIL)
202,838.10
Forward P/E
15.79
Dividend (Yield %)
3.58

Next Event

Novartis AG at Bank of America Merrill Lynch Global Healthcare Conference

Latest Developments

More

Biontech Says Request For COVID-19 Vaccine Approval Could Be Filed End Of Oct.

European Medicines Agency Approves Safety Label Update For Novartis Beovu

Novartis: planning to appeal against French watchdog's decision to fine it

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Novartis AG

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company's range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.

Industry

Major Drugs

Contact Info

Lichtstrasse 35

4056

Switzerland

+41.61.3241111

https://www.novartis.com/

Executive Leadership

Joerg Reinhardt

Independent Non-Executive Chairman of the Board

Alex Krauer

Honorary Chairman of the Board

Daniel L. Vasella

Honorary Chairman of the Board

Vasant Narasimhan

Chief Executive Officer, Member of the Executive Committee

Enrico Vanni

Independent Non-Executive Vice Chairman of the Board

Key Stats

2.04 mean rating - 27 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

49.1K

2018

51.9K

2019

47.4K

2020(E)

49.8K
EPS (USD)

2017

4.860

2018

5.150

2019

5.400

2020(E)

5.743
Price To Earnings (TTM)
28.86
Price To Sales (TTM)
4.51
Price To Book (MRQ)
3.85
Price To Cash Flow (TTM)
17.58
Total Debt To Equity (MRQ)
64.64
LT Debt To Equity (MRQ)
47.67
Return on Investment (TTM)
7.99
Return on Equity (TTM)
6.01

Latest News

Latest News

BioNTech buys German site from Novartis to boost vaccine output

BioNTech is buying a production site for the COVID-19 vaccine it is developing with Pfizer, aiming to boost output by several hundred million doses next year, and hopes to have the shot ready to file for approval in October.

Delaware judge deals Biogen another blow in Tecfidera patent fight

A federal judge in Delaware on Wednesday dealt another setback to drug company Biogen Inc in its effort to keep generic versions of its multiple sclerosis treatment Tecfidera off the market through patent litigation.

Novartis ties bond sale to malaria treatment access in sustainability push

Novartis raised 1.85 billion euros on Wednesday from the sale of a bond on which interest payments will rise if the drugmaker fails to expand access to medicines and programmes to combat malaria and leprosy in a number of developing countries.

Roche says two-thirds of Evrysdi patients had got rival treatments

Swiss drugmaker Roche on Monday said two-thirds of spinal muscular atrophy (SMA) patients now taking its newly approved drug Evrysdi have previously received rival treatments Zolgensma from Novartis or Biogen's Spinraza.

Novartis aims to expand Beovu use after safety fears hurt launch

Novartis's Beovu matched Regeneron's Eylea in vision clarity scores for a blindness-causing eye disease, the Swiss drugmaker said on Monday, after early safety stumbles for the medicine in another condition caused disappointing early sales.

Novartis says Beovu matched rival Eylea in visual acuity in eye disease

Novartis on Monday said its eye drug Beovu matched rival Eylea from Regeneron in visual acuity at one year in patients with diabetic macular edema (DME), as the Swiss drugmaker seeks to regain momentum with the drug after early safety stumbles.

France fines Roche, Novartis 444 million euros in ongoing eye drug clash

Switzerland's Novartis and Roche were fined 444 million euros (403.55 million pounds)by France, after its competition authority said on Wednesday they used abusive practices to push costly eye injection Lucentis over a cheaper drug.

Roche studies Ocrevus, experimental drug in bid to defend MS franchise

Roche aims to defend its multiple sclerosis (MS) franchise from rivals Novartis and Sanofi with new studies of its $4 billion-per-year Ocrevus product and advanced trials of an experimental medicine, fenebrutinib.

Novartis sets out new sustainability targets on patient outreach, carbon neutrality

Drugmaker Novartis on Tuesday announced new sustainability targets, including boosting access to its medicines and global outreach as well as aiming to make its supply chain carbon neutral by 2030.

Novartis push to expand cancer arsenal gets trial win against Pfizer drug

Novartis drug candidate asciminib notched a trial win against Pfizer's Bosulif, the Swiss drugmaker said on Wednesday, as it pushes to expand medicines for chronic myeloid leukaemia in patients for whom other treatments stopped working.

Novartis CEO says COVID-19 makes valuing takeover targets tougher

Swiss drugmaker Novartis AG has financial firepower for acquisitions even with net debt of $26 billion, though the COVID-19 pandemic has made it more difficult to value takeover candidates, Chief Executive Vas Narasimhan said in an interview.

Novartis immuno-oncology drug candidate fails skin cancer trial

Swiss drugmaker Novartis said on Saturday that its investigational spartalizumab immuno-oncology drug mixed with the approved medicines Tafinlar and Mekinist failed in a late-stage trial for a type of advanced skin cancer.

Novartis wins FDA approval to repurpose leukaemia drug against multiple sclerosis

Novartis on Thursday won U.S. Food and Drug Administration (FDA) approval to repurpose an 11-year-old blood cancer drug against multiple sclerosis as the Swiss drugmaker takes on rival Roche's big-selling Ocrevus for the autoimmune disorder.

U.S. court upholds patent for Novartis MS drug Gilenya

A U.S. district court upheld the validity of a patent for Swiss drugmaker Novartis' top-selling multiple sclerosis (MS) drug Gilenya, helping Novartis protect its blockbuster MS treatment from U.S. competition.

Novartis's Kymriah meets endpoint in follicular lymphoma trial

Novartis CAR-T cell therapy Kymriah met its primary endpoint at an interim analysis of a phase-II trial in patients with relapsed or refractory follicular lymphoma, the Swiss drugmaker said on Tuesday.

Novartis gets European approval for psoriasis drug Cosentyx

Novartis has received European Union approval for its Cosentyx drug to be a standard treatment for psoriasis in children, the company said on Monday.

Novartis sickle cell drug Adakveo put on path to EU approval

Novartis's sickle cell disease treatment Adakveo appears set for European approval after a key committee on Friday gave its backing to the drug that booked $36 million in first-half U.S. sales.

Whistleblower in Novartis kickback settlement to get $109 mln

The former Novartis sales representative whose whistleblower lawsuit against the drugmaker led to a $678 million settlement with the federal government and various states earlier this year will receive an award of $109.4 million.

Biogen to study Spinraza in combination with $2 million Novartis drug

One of medicine's costliest treatment areas could become even more pricey as Biogen seeks to layer its $750,000 spinal muscular atrophy drug on top of $2.1 million-per-patient Novartis gene therapy Zolgensma.

Novartis says Zolgensma patients kept gains as Biogen eyes follow-up trial

Novartis Chief Executive Vas Narasimhan said spinal muscular atrophy patients who got the Swiss drugmaker's Zolgensma maintained improvements, a response to Biogen's plan to test its drug Spinraza after Zolgensma treatment.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up